Human FLT3 Ligand Protein
Catalog No: FLT3L-HP001
- Species
- Human
- Expression System
- E. coli
- Activity
- Activity verified
Product overview
Recombinant Human FLT3 Ligand Protein is expressed in E. coli without tag. It contains amino acid residues Thr27-Ala181 (UniProt accession: P49771-1).
Product Details
- Molecular Aliases
- FL; Flt3 ligand; Flt3L; FLT3LG; SL cytokine; Flt-3 Ligand; Flt-3L
- Protein Length
- Thr27-Ala181
- Expression System
- E. coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 17.61 kDa same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 0.1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human FLT3 Ligand on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human FLT3 Ligand is greater than 95% as determined by SEC-HPLC.
Immobilized Human FLT3 Ligand, No Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human FLT3, hFc Tag with the EC50 of 21.7ng/ml determined by ELISA.
The ED50 was determined by the dose-dependent stimulation of the proliferation of human AML5 cells is < 2.0 ng/ml. (QC Test)
Background
Flt‑3 Ligand, also known as FL, is an alpha -helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages.Stimulates the proliferation of early hematopoietic cells by activating FLT3. Synergizes well with a number of other colony stimulating factors and interleukins.
References
- Small D. Targeting FLT3 for the Treatment of Leukemia[J]. Seminars in Hematology, 2008, 45(supp-S2).
Have questions about this product?
Our technical team can help with product selection, application questions and order support.